Section

446.01: General Provisions

446.02: Definitions

446.03: General Rate Provisions and Payment

446.04: Special Contracts

446.05: Reporting Requirements

446.06: Severability

446.01: General Provisions

(1) Scope and Purpose. 101 CMR 446.00 governs the rates of payment to certain community health care providers to be used by all governmental units for services provided to publicly aided individuals. The rates set forth in 101 CMR 446.03(1), (4), and (5) also apply to such services paid for by governmental units for individuals covered by M.G.L. c. 152 (the Workers’ Compensation Act). These rates are for services related to Coronavirus Disease 2019 (COVID-19).

(2) Applicable Dates of Service. Rates contained in 101 CMR 446.00 apply for dates of service on or after November 25, 2022, except as otherwise noted.

(3) Disclaimer of Authorization of Services. 101 CMR 446.00 is not authorization for or approval of the services for which rates are determined pursuant to 101 CMR 446.00. Governmental units that purchase services are responsible for the definition, authorization, and approval of care and services provided to publicly aided individuals.

(4) Coverage. The rates of payment in 101 CMR 446.00 constitute payment in full for all services provided by an eligible provider, including administration and professional supervision services. The payment rates will apply to COVID-19 services provided by eligible providers to publicly aided individuals under the conditions described by the purchasing governmental unit.

(5) Coding Updates and Corrections. EOHHS may publish service code updates and corrections in the form of an administrative bulletin. Updates may reference coding systems including, but not limited to, the *Healthcare Common Procedure Coding System (HCPCS).* The publication of such updates and corrections will list

(a) codes for which the code numbers change, with the corresponding cross references between existing and new codes and the codes being replaced. Rates for such new codes are set at the rate of the code that is being replaced;

(b) codes for which the code number remains the same but the description has changed;

(c) deleted codes for which there are no corresponding new codes; and

(d) codes for entirely new services that require pricing, or codes that had been previously added at individual consideration (I.C.). EOHHS may list and price these codes according to the rate methodology used in setting rates when Medicare fees are available. When Medicare fees are not available, EOHHS may apply I.C. payment for these codes until appropriate rates can be developed.

(6) Administrative Bulletins. EOHHS may issue administrative bulletins to clarify its policy on and understanding of substantive provisions of 101 CMR 446.00, or to issue coding updates and corrections under 101 CMR 446.01(5).

446.02: Definitions

As used in 101 CMR 446.00, terms have the meanings in 101 CMR 446.02, except as otherwise provided.

Clinical Care Team. The staff necessary to provide I&R Services to guests at an I&R site. The clinical care team may include physicians, nurse practitioners, physician assistants, registered nurses, licensed practical nurses, certified nursing assistants, home health aides, masters of social work, licensed independent clinical social workers, and administrative support staff. EOHHS may approve other staff types to be part of the clinical care team, including staff with different clinical qualifications than those listed herein, as appropriate. The make-up of the clinical care team for each I&R community health center will be established in the special conditions amendment to each I&R community health center’s provider contract.

Commonwealth COVID-19 Vaccination Plan. The plan describing the administration of COVID-19 vaccinations within the Commonwealth, including eligibility criteria and phasing, available at [www.mass.gov/info-details/massachusetts-covid-19-vaccination-phases](http://www.mass.gov/info-details/massachusetts-covid-19-vaccination-phases).

COVID-19 Services. Services relating to the March 10, 2020, Declaration of State of Emergency within the Commonwealth due to the 2019 novel coronavirus (COVID-19), for which payment rates are set under 101 CMR 446.00.

Eligible Additional Individuals. As determined by the governmental unit or its designee, any

(a) family member of an eligible resident currently residing in the eligible resident’s household; or

(b) home health worker who provides regular care to an eligible resident in the eligible resident’s household.

Eligible Provider. A person, partnership, corporation, governmental unit, or other entity that provides authorized COVID-19 services and that also meets such conditions of participation as have been or may be adopted from time to time by a governmental unit purchasing COVID-19 services.

Eligible Resident. A Massachusetts resident determined to be eligible for in-home vaccination services by the governmental unit or its designee.

EOHHS. The Executive Office of Health and Human Services established under M.G.L. c. 6A.

Governmental Unit. The Commonwealth of Massachusetts or any of its departments, agencies, boards, commissions, or political subdivisions.

Household. A home or residence within the Commonwealth in which at least one eligible resident resides, including congregate care facilities and other congregate housing, but excluding any facility or unit licensed by DPH as a long-term-care facility or unit pursuant to 105 CMR 150.000: *Standards for Long-term Care Facilities*.

In-home Vaccination Provider. An eligible provider who provides in-home vaccination services pursuant to a contract between the governmental unit and the eligible provider.

In-home Vaccination Services. COVID-19 vaccine administration services performed in a household by an in-home vaccination provider pursuant to a contract between the governmental unit and the in-home vaccination provider.

I&R Community Health Center. A community health center that has agreed to provide services at an I&R site through an executed special conditions amendment to its provider contract.

I&R Services. The services that the clinical care team at an I&R community health center must provide, as provided by the special conditions amendment to the provider contract.

I&R Site. A location, such as a hotel or motel, that separately contracts with EOHHS to provide safe, isolated lodging for individuals with a COVID-19 diagnosis.

Other Vaccinable Individuals. Residents of the Commonwealth who are neither eligible residents nor eligible additional individuals, but who are otherwise eligible to receive a COVID-19 vaccination in accordance with the Commonwealth’s COVID-19 vaccination plan.

Publicly Aided Individual. A person for whose medical and other services a governmental unit is in whole or in part liable under a statutory program.

Waste Prevention Vaccinations. COVID-19 vaccinations administered by an in-home vaccination provider to other vaccinable individuals in any setting solely to avoid wasting COVID-19 vaccine doses that would otherwise spoil.

446.03: General Rate Provisions and Payment

(1) Community Health Centers.

(a) General Rate Determination. Rates of payment for services for which 101 CMR 446.03(1) applies are the lowest of

1. the eligible provider’s usual fee to patients other than publicly aided individuals;

2. the eligible provider’s actual charge submitted; or

3. the schedule of allowable fees set forth in 101 CMR 446.03(1)(c), taking into account appropriate modifiers and any other applicable rate provisions in accordance with 101 CMR 446.03(1).

(b) Defined Terms. Terms used in 101 CMR 446.03(1) that have not been defined elsewhere in 101 CMR 446.00 have the meanings ascribed to those terms in 101 CMR 304.02: *Definitions*.

(c) Allowable Fee for I&R Services through Alternative Payment Methodology.

1. Governmental units may pay I&R community health centers for I&R services they provide through a weekly, facility-specific, all-inclusive rate established through the alternative payment methodology described in 101 CMR 446.03(1)(c)1. through 2. This rate must be set forth and agreed to by each I&R community health center and the governmental unit through a contract or special conditions amendment to the provider contract, sufficient to cover the following allowable costs associated with the provision of I&R services, as agreed to by the governmental unit and the I&R community health center.

a. The direct labor costs for the clinical care team, staffed appropriately to meet the clinical and administrative needs of the I&R site.

b. The costs to acquire and maintain sufficient amounts of medical supplies necessary to provide I&R services at the I&R site.

c. Appropriate set-up and other one-time costs associated with the provision of I&R services at the I&R site, which may include information technology equipment and services and office supplies.

d. For the costs described in 101 CMR 446.03(1)(c)a. through c. to be considered allowable, the cost must, at a minimum, be reasonable, directly related to the provision of I&R services, and identified in the contract or special conditions amendment to the I&R community health center’s provider contract.

2. Billing and Disbursement of Payment. I&R community health centers must bill the governmental unit for the I&R services provided pursuant to 101 CMR 446.03(1)(c) and a contract or special conditions amendment to the provider contract through weekly invoice. The government unit will pay the I&R community health center for such services weekly, upon receipt of such invoice, consistent with the terms of the contract or special conditions amendment to the provider contract.

(d) Supplemental Payments to Community Health Centers.

1. Subject to federal approval, community health centers that are federally qualified health centers in Massachusetts will receive one-time, health center-specific supplemental payments to account for services rendered during calendar year 2021. The one-time, health center-specific supplemental payment will be paid to each community health center by the end of the second calendar quarter of 2021. A community health center’s health center-specific supplemental payment was calculated based on the following components:

a. an amount equal to a portion of the community health center’s average monthly claims, based on annualized data from January and February 2020, paid by MassHealth and MassHealth managed care entities, as determined by EOHHS;

b. as applicable, the amount that would have been paid to the community health center, if not for the scheduled decrease to the community health center's 340B supplemental payment under 101 CMR 304.04(3): *340B Transition Supplemental Payments*, which took effect on January 1, 2021; and

c. as applicable, an amount determined by EOHHS for the heightened costs faced by community health centers with greater than 100,000 annual individual medical visits, based on annualized data from January and February 2020.

2. The supplemental payments, as described in 101 CMR 446.03(1)(d)1., will equal the following amounts for each community health center:

| **Community Health Center** | **Supplemental Payment** |
| --- | --- |
| Boston Health Care for the Homeless | $4,839,557 |
| Brockton Neighborhood Health Center, Inc. | $2,810,993 |
| Caring Health Center, Inc. | $1,318,873 |
| Charles River Community Health | $666,458 |
| Community Health Center of Cape Cod | $774,741 |
| Community Health Center of Franklin County | $353,940 |
| Community Health Connections Family Health Center | $1,418,345 |
| Community Health Programs CHC | $491,729 |
| Dimock Community Health Center | $876,407 |
| Duffy Health Center | $361,499 |
| Edward M. Kennedy Community Health Center | $1,713,369 |
| Family Health Center of Worcester | $2,545,653 |
| Fenway Community Health Center | $1,700,062 |
| Greater Lawrence Family Health Center, Inc. | $5,340,713 |
| Greater New Bedford Community Health Center | $1,329,984 |
| Harbor Health Services, Inc. | $1,780,265 |
| Harvard Street Neighborhood Health Center | $379,641 |
| Healthfirst Family Care Center, Inc. | $841,430 |
| Hilltown Community Health Centers, Inc. | $295,175 |
| Holyoke Health Center | $2,910,268 |
| Island Health Care | $30,351 |
| Lowell Community Health Center | $2,738,370 |
| Lynn Community Health Center | $3,909,622 |
| Manet Community Health Center | $832,276 |
| Mattapan Community H C | $402,987 |
| North End Waterfront Health | $336,460 |
| North Shore Community Health, Inc. | $815,613 |
| Outer Cape Health Services, Inc. | $586,726 |
| South Cove Community Health Center | $1,978,226 |
| Springfield Health Services for the Homeless | $138,746 |
| Stanley Street Treatment and Resources (SSTAR) | $2,832,520 |
| Uphams’ Corner Health Center | $715,148 |
| Whittier Street Health Center | $908,376 |
| **TOTAL** | **$48,974,525** |

(2) Medicine.

(a) General Rate Determination. Rates of payment for services for which 101 CMR 446.03(2) applies are the lowest of

1. the eligible provider’s usual fee to patients other than publicly aided individuals;

2. the eligible provider’s actual charge submitted; or

3. the schedule of allowable fees set forth in 101 CMR 446.03(2)(e), taking into account appropriate modifiers and any other applicable rate provisions in accordance with 101 CMR 446.03(2).

(b) Individual Consideration. Medical services services designated “I.C.” are individually considered items. The governmental unit or purchaser analyzes the eligible provider’s report of services rendered and charges submitted under the appropriate unlisted services or procedures category. The governmental unit or purchaser determines appropriate payment for procedures designated I.C. in accordance with the following standards and criteria:

1. the amount of time required to perform the service;

2. the degree of skill required to perform the service;

3. the severity or complexity of the patient’s disease, disorder, or disability;

4. any applicable relative-value studies;

5. any complications or other circumstances that may be deemed relevant;

6. the policies, procedures, and practices of other third party insurers;

7. the payment rate for prescribed drugs as set forth in 101 CMR 331.00: *Prescribed Drugs*; and

8. a copy of the current invoice from the supplier.

(c) Defined Terms. Terms used in 101 CMR 446.03(2) that have not been defined elsewhere in 101 CMR 446.00 have the meanings in 101 CMR 317.02: *General Definitions*.

(d) Codes and Modifiers.

1. Except as otherwise provided, the codes and modifiers for the services described in 101 CMR 446.03(2) are as defined in 101 CMR 317.04(3): *Modifiers* and 101 CMR 317.04(4): *Fee Schedule*.

2. The modifier “SL”: State supplied vaccine or antibodies. This modifier is to be applied to codes to identify vaccine or antibodies provided at no cost, whether by the Massachusetts Department of Public Health or other federal or state agency. No payment shall be made for codes with this modifier.

(e) Allowable Fee for Remote Patient Monitoring (RPM) Bundled Services. The following code, modifier, and fee apply for the provision of RPM bundled services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 99423 – U9 | $870.72 | Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 21 or more minutes.  (Used for COVID-19 remote patient monitoring bundled services provided through any appropriate technology or modality, including up to 7 days of daily check-ins for evaluation and monitoring; multidisciplinary clinical team reviews of a member’s status and needs; appropriate physician oversight; necessary care coordination; and provision of a thermometer and pulse oximeter for remote monitoring.) |

(f) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after April 1, 2021. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 91303 SL | $0.00 | Janssen COVID-19 Vaccine (SARSCOV2 VAC AD26 0.5 ml IM) |
| 0031A | $45.87 | Janssen COVID-19 Vaccine Administration (ADM SARSCOV2 VAC AD26 0.5 ml) |
| 91300 SL | $0.00 | Pfizer-Biontech COVID-19 Vaccine (Purple Cap) (SARSCOV2 VAC 30MCG/0.3ML IM) |
| 0001A | $45.87 | Pfizer-Biontech COVID-19 Vaccine Administration (Purple Cap) – First Dose (ADM SARSCOV2 30MCG/0.3ML 1st) |
| 0002A | $45.87 | Pfizer-Biontech COVID-19 Vaccine Administration (Purple Cap) – Second Dose (ADM SARSCOV2 30MCG/0.3ML 2ND) |
| 91301 SL | $0.00 | Moderna COVID-19 Vaccine (SARSCOV2 VAC 100MCG/0.5ML IM) |
| 0011A | $45.87 | Moderna COVID-19 Vaccine Administration – First Dose (ADM SARSCOV2 100MCG/0.5ML1ST) |
| 0012A | $45.87 | Moderna COVID-19 Vaccine Administration – Second Dose (ADM SARSCOV2 100MCG/0.5ML2ND) |
| D1701 | $45.87 | Pfizer-BioNTech COVID-19 Vaccine Administration – First Dose (SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 1) |
| D1702 | $45.87 | Pfizer-BioNTech COVID-19 Vaccine Administration – Second Dose (SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 2) |
| D1703 | $45.87 | Moderna COVID-19 Vaccine Administration – First Dose (SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 1) |
| D1704 | $45.87 | Moderna COVID-19 Vaccine Administration – Second Dose (SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 2) |
| D1707 | $45.87 | Janssen Covid-19 Vaccine Administration (SARSCOV2 COVID-19 VAC Ad26 5x1010 VP/.5mL IM SINGLE DOSE) |

(g) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after August 12, 2021. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 0003A | $45.87 | Pfizer-BioNTech COVID-19 Vaccine (Purple Cap) Administration – Third Dose (ADM SARSCOV2 30MCG/0.3ML 3RD) |
| 0013A | $45.87 | Moderna COVID-19 Vaccine Administration – Third Dose (ADM SARSCOV2 100MCG/0.5ML3RD) |

(h) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after September 22, 2021. The following code and fee applies for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 0004A | $45.87 | Pfizer-BioNTech COVID-19 Vaccine (Purple Cap) Administration – Booster (ADM SARSCOV2 30MCG/0.3ML BST) |

(i) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after October 20, 2021. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 0034A | $45.87 | Janssen COVID-19 Vaccine Administration -  Booster[ ( (ADM SARSCOV2 VAC AD26 .5ML B) |
| 91306 SL | $0.00 | Moderna COVID-19 Vaccine (Low Dose) (SARSCOV2 VAC 50MCG/0.25ML IM) |
| 0064A | $45.87 | Moderna COVID-19 Vaccine (Low Dose) Administration – Booster (ADM SARSCOV2 50MCG/0.25MLBST) |

(j) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after October 29, 2021. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 91307 SL | $0.00 | Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) |
| 0071A | $45.87 | Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration - First dose (ADM SARSCV2 10MCG TRS-SUCR 1) |
| 0072A | $45.87 | Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration - Second dose (ADM SARSCV2 10MCG TRS-SUCR 2) |

(k) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after January 3, 2022. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

|  |  |  |
| --- | --- | --- |
| **Code** | **Allowable Fee** | **Description of Code** |
| 91305 SL | $0.00 | Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) (SARSCOV2 VAC 30 MCG TRS-SUCR) |
| 0051A | $45.87 | Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - First dose (ADM SARSCV2 30MCG TRS-SUCR 1) |
| 0052A | $45.87 | Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Second dose (ADM SARSCV2 30MCG TRS-SUCR 2) |
| 0053A | $45.87 | Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Third dose (ADM SARSCV2 30MCG TRS-SUCR 3) |
| 0054A | $45.87 | Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration – Booster (ADM SARSCV2 30MCG TRS-SUCR B) |
| 0073A | $45.87 | Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose (ADM SARSCV2 10MCG TRS-SUCR 3) |

(l) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after March 22, 2022. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

|  |  |  |
| --- | --- | --- |
| **Code** | **Allowable Fee** | **Description of Code** |
| D1708 | $45.87 | D1708 Pfizer-BioNTech COVID-19 vaccine administration – third dose (SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE 3) |
| D1709 | $45.87 | D1709 Pfizer-BioNTech Covid-19 vaccine administration – booster dose (SARSCOV2 COVID-19 VAC mRNA 30mcg/0.3mL IM DOSE BOOSTER) |
| D1710 | $45.87 | D1710 Moderna COVID-19 vaccine administration – third dose (SARSCOV2 COVID-19 VAC mRNA 100mcg/0.5mL IM DOSE 3) |
| D1711 | $45.87 | D1711 Moderna COVID-19 vaccine administration – booster dose (SARSCOV2 COVID-19 VAC mRNA 50mcg/0.25mL IM DOSE BOOSTER) |
| D1712 | $45.87 | D1712 Janssen COVID-19 vaccine administration - booster dose (SARSCOV2 COVID-19 VAC Ad26 5x1010 VP/0.5mL IM DOSE BOOSTER) |
| D1713 | $45.87 | D1713 Pfizer-BioNTech COVID-19 vaccine administration tris-sucrose pediatric – first dose (SARSCOV2 COVID-19 VAC mRNA 10mcg/0.2mL tris-sucrose IM DOSE 1) |
| D1714 | $45.87 | D1714 Pfizer-BioNTech COVID-19 vaccine administration tris-sucrose pediatric – second dose (SARSCOV2 COVID-19 VAC mRNA 10mcg/0.2mL tris-sucrose IM DOSE 2) |

(m) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after March 29, 2022. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 91309 SL | $0.00 | Moderna Covid-19 Vaccine (Aged 6 years through 11 years or aged 18 years and older) (Blue Cap with purple border) 50MCG/0.5ML (SARSCOV2 VAC 50MCG/0.5ML IM) |
| 0094A | $45.87 | Moderna Covid-19 Vaccine (Aged 18 years and older) (Blue Cap with purple border) 50MCG/0.5ML Administration – Booster (ADM SARSCOV2 50MCG/0.5 MLBST) |

(n) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after May 17, 2022. The following code and fee applies for the listed COVID-19 vaccine and its administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 0074A | $45.87 | Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration – Booster (ADM SARSCV2 10MCG TRS-SUCR B) |

(o) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after June 17, 2022. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 91308 SL | $0.00 | Pfizer-BioNTech Covid-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) (SARSCOV2 VAC 3MCG TRS-SUCR) |
| 0081A | $45.87 | Pfizer-BioNTech Covid-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) Administration - First dose (ADM SARSCOV2 3MCG TRS-SUCR 1) |
| 0082A | $45.87 | Pfizer-BioNTech Covid-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) Administration - Second dose (ADM SARSCOV2 3MCG TRS-SUCR 2) |
| 0083A | $45.87 | Pfizer-BioNTech Covid-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) Administration - Third dose (ADM SARSCOV2 3MCG TRS-SUCR 3) |
| 0091A | $45.87 | Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) Administration - First dose (ADM SARSCOV2 50 MCG/.5 ML1ST) |
| 0092A | $45.87 | Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) Administration - Second dose (ADM SARSCOV2 50 MCG/.5 ML2ND) |
| 0093A | $45.87 | Moderna Covid-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) Administration - Third dose (ADM SARSCOV2 50 MCG/.5 ML3RD) |
| 91311 SL | $0.00 | Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) 250MCG/0.25ML (SARSCOV2 VAC 25MCG/0.25ML IM) |
| 0111A | $45.87 | Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) Administration - First dose (ADM SARSCOV2 25MCG/0.25ML1ST) |
| 0112A | $45.87 | Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) Administration – Second dose (ADM SARSCOV2 25MCG/0.25ML2ND) |
| 0113A | $45.87 | Moderna Covid-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) Administration - Third dose (ADM SARSCOV2 25MCG/0.25ML3RD) |

(p) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after July 13, 2022. The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 91304 SL | $0.00 | Novavax Covid-19 Vaccine, Adjuvanted (Aged 12 years and older) (SARSCOV2 VAC 5MCG/0.5ML IM) |
| 0041A | $45.87 | Novavax Covid-19 Vaccine, Adjuvanted  Administration – First Dose (ADM SARSCOV2 5MCG/0.5ML 1ST) |
| 0042A | $45.87 | Novavax Covid-19 Vaccine, Adjuvanted  Administration – Second Dose ADM SARSCOV2 5MCG/0.5ML 2ND |

(q) Allowable Fee for COVID-19 Vaccine and Vaccine Administration Applicable for Dates of Service on or after August 31, 2022. - The following codes and fees apply for the listed COVID-19 vaccines and their administration.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| 91313 SL | $0.00 | Moderna COVID-19 Vaccine, Bivalent Product (Aged 18 years and older) (Dark Blue Cap with gray border) (SARSCOV2 VAC BVL 50MCG/0.5ML) |
| 0134A | $45.87 | Moderna COVID-19 Vaccine, Bivalent (Aged 18 years and older) (Dark Blue Cap with gray border) Administration – Booster Dose (ADM SARSCV2 BVL 50MCG/.5ML B) |
| 91312 SL | $0.00 | Pfizer-BioNTech COVID-19 Vaccine, Bivalent Product (Aged 12 years and older) (Gray Cap) (SARSCOV2 VAC BVL 30MCG/0.3M) |
| 0124A | $45.87 | Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Gray Cap) Administration – Booster Dose (ADM SARSCV2 BVL 30MCG/.3ML B) |

(r) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after May 6, 2021. The following codes and fees apply for the listed COVID-19 treatment services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0243 SL | $0.00 | Injection, casirivimab and imdevimab, 2400 mg |
| M0243 | $450.00 | Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring |
| M0244 | $750.00 | Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the federal COVID-19 public health emergency |
| Q0245 SL | $0.00 | Injection, bamlanivimab and etesevimab, 2100 mg |
| M0245 | $450.00 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
| M0246 | $750.00 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the federal COVID-19 public health emergency |

(s) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after May 26, 2021. The following codes and fees apply for the listed COVID-19 treatment services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0247 | $2,394.00 | Injection, sotrovimab, 500 mg |
| M0247 | $450.00 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
| M0248 | $750.00 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the federal COVID-19 public health emergency |

(t) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after June 3, 2021. The following codes and fees apply for the listed COVID-19 treatment service.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0244 SL | $0.00 | Injection, casirivimab and imdevimab, 1200 mg |

(u) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after June 24, 2021. The following codes and fees apply for the listed COVID-19 treatment services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0249 | $6.57 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg |
| M0249 | $450.00 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose |
| M0250 | $450.00 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose |

(v) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after July 31, 2021. The following codes and fees apply for the listed COVID-19 treatment services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0240 SL | $0.00 | Injection, casirivimab and imdevimab, 600 mg |
| M0240 | $450.00 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
| M0241 | $750.00 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses |

(w) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after December 8, 2021. The following codes and fees apply for the listed COVID-19 treatment services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0220 SL | $0.00 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg |
| M0220 | $150.50 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring |
| M0221 | $250.50 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency |

(x) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after February 11, 2022. The following codes and fees apply for the listed COVID-19 treatment services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0222 SL | $0.00 | Injection, bebtelovimab, 175 mg |
| M0222 | $350.50 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
| M0223 | $550.50 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the covid-19 public health emergency |

(y) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after April 24, 2022. The following code and fee applies for the listed COVID-19 treatment service.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0221 SL | $0.00 | Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg |

(z) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after April 1, 2022. The following code and fee applies for the listed COVID-19 treatment services.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| J0248 | $5.51 | Injection, remdesivir, 1 mg |

(aa) Allowable Fee for COVID-19 Treatment Applicable for Dates of Service on or after August 15, 2022. The following code and fee applies for the listed COVID-19 treatment service.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| Q0222 | $2394.00 | Injection, bebtelovimab, 175 mg |

# (3) Durable Medical Equipment, Oxygen and Respiratory Therapy Equipment, and Supplies.

(a) General Rate Determination. Rates of payment for services for which 101 CMR 446.03(3) applies are the lowest of

1. the eligible provider’s usual fee to patients other than publicly aided individuals;

2. the eligible provider’s actual charge submitted; or

3. the schedule of allowable fees set forth in 101 CMR 446.03(3)(d), (e), (f), and (g), taking into account appropriate modifiers and any other applicable rate provisions in accordance with 101 CMR 446.03(3).

(b) Defined Terms. Terms used in 101 CMR 446.03(3) have the meaning defined in 101 CMR 322.02: *General Definitions*.

(c) Codes and Modifiers. Except as otherwise provided, the codes and modifiers for the DME services described in 101 CMR 446.03(3) are as defined in 101 CMR 322.03(13): *Modifiers* and 101 CMR 322.06: *Allowable Fees and Rate Schedule*.

(d) Allowable Fee for Distribution of Personal Protective Equipment (PPE).

1. Authorization for the provision of, and billing and payment for, distribution of PPE to certain MassHealth members is governed by an executed special conditions amendment to a MassHealth DME provider’s provider contract.

2. The fee and modifier in 101 CMR 446.03(3)(d)2. apply for distribution of PPE.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| E1399 U9 | $40.00 | Durable medical equipment, miscellaneous. (Used for PPE distribution services, specifically the packaging, preparing, and delivering or shipping of a 2-week supply PPE kit to an authorized individual during the COVID-19 public health emergency) |

(e) Allowable Fee for Nonsterile Gloves. The following fee in 101 CMR 446.03(3)(e) is in effect for nonsterile gloves.

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| A4927 | $11.00 | Gloves, non-sterile, per 100 |

(f) Allowable Fee for Over-the-counter Diagnostic Tests for SARS-CoV-2. For over-the-counter diagnostic tests for SARS-CoV-2 supplied through pharmacies to MassHealth members for dates of service on or after January 14, 2022, EOHHS may set allowable fees no higher than $12.00 per test. EOHHS may set the allowable fee for particular tests below $12.00 per test, so long as the allowable fee is equal to or greater than the lowest retail rate available to MassHealth members in Massachusetts. For over-the-counter tests supplied through pharmacies for MassHealth members, EOHHS will designate allowable fees via Pharmacy Facts, provider bulletin, or other written issuance, consistent with this section. The $12.00 maximum allowable fee per test rate may be adjusted via administrative bulletin if guidance from the federal Departments of Labor, Health and Human Services, or the Treasury changes regarding rates payable by commercial plans.

(g) Allowable Fee for Formula and Thickening Agents. For formula and thickening agents dispensed through pharmacies to MassHealth members for dates of service on or after December 16, 2021, the allowable fee is the wholesale acquisition cost. For purposes of this section, the wholesale acquisition cost means the manufacturer’s price published in a national price compendium or other publicly available source or an adjusted list price.

(h) Reporting Requirements. Reporting requirements for 101 CMR 446.03(3) are those in 101 CMR 322.04: *Reporting Requirements*.

(4) Ambulance and Wheelchair Van Services.

(a) General Rate Determination. Rates of payment for services for which 101 CMR 446.03(4) applies are the lowest of

1. the eligible provider’s usual fee to patients other than publicly aided individuals;

2. the eligible provider’s actual charge submitted; or

3. the schedule of allowable fees set forth in 101 CMR 446.03(4)(c), taking into account appropriate modifiers and any other applicable rate provisions in accordance with 101 CMR 446.03(4).

(b) Defined Terms. Terms used in 101 CMR 446.03(4) that have not been defined elsewhere in 101 CMR 446.00 have the meanings in 101 CMR 327.02: *General Definitions*.

(c) Allowable Fees for Ambulance and Wheelchair Van Services. The following code and allowable fee applies, notwithstanding the definition of “trip” in 101 CMR 327.02: *General Definitions.*

| **Code** | **Allowable Fee** | **Description of Code** |
| --- | --- | --- |
| A0998 | $157.88 | Ambulance response and treatment, no transport (Used for medically necessary visits to patients to obtain and transport specimens for COVID-19 diagnostic testing) |
| A0120 | $100.00 | Nonemergency transportation: mini-bus, mountain area transports, or other transportation systems. (Each way. Used only for non-emergency wheelchair van transport for a person under investigation or known to have COVID-19.) |

(d) Billing Certification. Each eligible provider who submits an invoice to a governmental unit for authorized ambulance services must certify the accuracy of the level of services provided, as listed on its invoice.

(e) Reporting Requirements. Reporting requirements under 101 CMR 446.03(4) are those in 101 CMR 327.05: *Reporting Requirements*.

(5) Prescribed Drugs.

(a) Defined Terms. Terms used in 101 CMR 446.03(5) that have not been defined elsewhere in 101 CMR 446.00 have the meanings in 101 CMR 331.02: *General Definitions*.

(b) Delivery Fee. Eligible providers will receive a payment adjustment to the professional dispensing fee when medications are delivered to a personal residence (including homeless shelters). The payment adjustment will be the lower of the provider’s usual and customary charge for prescription delivery or $8.00, and will be made only when the MassHealth agency is the primary payer. Payment of this fee by MassHealth will occur only in such circumstances as as designated by Pharmacy Facts, provider bulletin, or other written issuance from the MassHealth agency.

(c) Reporting Requirements. Reporting requirements for 101 CMR 446.03(5) are those in 101 CMR 331.03: *Reporting Requirements*.

(6) Testing Services.

(a) General Rate Determination. Rates of payment for services under which 101 CMR 446.03(6) applies are the lowest of

1. the eligible provider's usual and customary charge to patients other than publicly aided individuals;

2. the eligible provider's actual charge submitted; or

3. the schedule of allowable fees set forth in 101 CMR 446.03(6)(d) through (f), taking into account appropriate modifiers and any other applicable rate provisions in accordance with 101 CMR 446.03(6).

(b) Defined Terms. Terms used in 101 CMR 446.03(6) that have not been defined elsewhere in 101 CMR 446.00 have the meanings in 101 CMR 320.02: *Definitions.*

(c) Individual Consideration (I.C.). Unlisted procedures and laboratory tests designated I.C. are individually considered items. The eligible provider's bill for such a test must be accompanied by a brief report of the procedure or test performed and the eligible provider's usual and customary charge for that procedure or test. Determination of appropriate payments for procedures and tests designated I.C. are in accordance with the following standards and criteria:

1. time required to perform the procedure;

2. degree of skill required in the procedure performed;

3. severity or complexity of the patient's disease, disorder, or disability;

4. policies, procedures, and practices of other third-party purchasers of care;

5. prevailing medical-laboratory ethics and accepted custom of the medical-laboratory community; and

6. such other standards and criteria as may be adopted by EOHHS. In no event may an eligible provider bill or be paid in excess of the usual and customary charge for the service.

(d) Allowable Fees for Certain Individual COVID-19 Testing Services – Not Including Laboratory Analysis. The allowable fees in 101 CMR 446.03(6)(d) apply for the listed COVID-19 testing services performed by an eligible provider at a mobile testing site where the eligible provider is not required to perform, pay for, or contract for the laboratory analysis.

| **Allowable Fee** | **Description of Service** |
| --- | --- |
| $20.81 | Ordering, resulting, and follow-up counseling services, per COVID-19 test completed by an eligible mobile testing vendor where the provider is not required to perform, pay for, or contract for the laboratory analysis |
| $60.00 | COVID-19 specimen collection completed by an mobile testing vendor, including test administration or observation, and specimen transport services, per hour, per staff member |

(e) Allowable Fees for Certain Individual COVID-19 Testing Services – Including Laboratory Analysis. The allowable fees in 101 CMR 446.03(6)(e) apply for the listed COVID-19 testing services where the eligible provider is required to perform, pay for, or contract for the laboratory analysis.

|  |  |
| --- | --- |
| **Allowable Fee** | **Description of Service** |
| $144.27 | Site-based or mobile COVID-19 testing service administered or observed by an eligible provider, including specimen collection, laboratory processing, ordering, resulting, and follow-up counseling services, per test |
| Individual Consideration | Self-administered COVID-19 testing service completed by an eligible provider, including transport of testing materials, laboratory processing, ordering, resulting, and follow-up counseling services, per test |

(f) Allowable Fees for Certain Pooled COVID-19 Testing Services – Including Laboratory Analysis.

1. Effective for dates of service on or after February 4, 2021, governmental units may pay eligible providers for pooled COVID-19 testing services, including laboratory analysis, through a per-pool rate and a rate for individual testing, if any, provided by the pooled testing provider as part of a pooled testing program. The rates must be set forth and agreed to by each eligible provider and the governmental unit through a contract or special conditions amendment to the provider contract. Specimen collection costs, specimen transport costs, and administrative fees may be billed separately from testing services.

2. Eligible providers must bill the governmental unit for the pooled COVID-19 testing services provided pursuant to 101 CMR 446.03(6)(f) and a contract or special conditions amendment to the provider contract, consistent with the terms of the contract or special conditions amendment to the provider contract. The governmental unit will pay the eligible provider for such services, upon receipt of such invoice, consistent with the terms of the contract or special conditions amendment to the provider contract.

(g) Billing Certification. Each eligible provider who submits an invoice to a governmental unit for authorized services under 101 CMR 446.03(6) must certify the accuracy of the level of services provided, as listed on its invoice.

(7) Allowable Fee for In-home Vaccination Services and Waste Prevention Vaccinations Provided Pursuant to a Contract Between an In-home Vaccination Provider and a Governmental Unit.

(a) General Rate Determination. Rates of payment for services for which 101 CMR 446.03(7) applies are the lowest of

1. the in-home vaccination provider’s usual fee to patients other than publicly aided individuals;

2. the in-home vaccination provider’s actual charge submitted; or

3. the schedule of allowable fees set forth in 101 CMR 446.03(7)(c), taking into account appropriate modifiers and any other applicable rate provisions in accordance with 101 CMR 446.03(7).

(b) Defined Terms. Terms used in 101 CMR 446.03(7) that have not been defined elsewhere in 101 CMR 446.00 have the meanings ascribed to those terms in the contract between the in-home vaccination provider and the governmental unit.

(c) Allowable Fee for In-home Vaccination Services and Waste Prevention Vaccinations Provided by In-home Vaccination Providers. The following fees apply for the listed in-home vaccination services and waste prevention vaccinations rendered by in-home vaccination providers.

|  |  |
| --- | --- |
| **SERVICE** | **ALLOWABLE FEE** |
| In-home vaccination services rendered to eligible residents, in-home vaccination services rendered to eligible additional individuals, or waste prevention vaccinations administered to other vaccinable individuals | $150.00 per COVID-19 vaccine dose administered |

## 446.04: Special Contracts

Notwithstanding 101 CMR 446.03, a governmental unit may enter into a special contract with an eligible provider under which the governmental unit will pay for services authorized but not listed herein, or authorized services performed in exceptional circumstances.

## 446.05: Reporting Requirements

(1) Required Reports. Except as otherwise provided, reporting requirements are governed by 957 CMR 6.00: *Cost Reporting Requirements*.

(2) Penalty for Noncompliance. Except as otherwise provided, the purchasing governmental unit may impose a penalty in the amount of up to 15% of its payments to any provider that fails to submit required information. The purchasing governmental unit will notify the provider in advance of its intention to impose a penalty under 101 CMR 446.05(2).

## 446.06: Severability

The provisions of 101 CMR 446.00 are severable and if any provisions of 101 CMR 446.00 or the application of such provisions to any person or circumstances is held to be invalid or unconstitutional, such invalidity will not be construed to affect the validity or constitutionality of any remaining provisions of 101 CMR 446.00 or application of such provisions to eligible providers or circumstances other than those held invalid.

## REGULATORY AUTHORITY

101 CMR 446.00: M.G.L. c.118E.